Lessons learned from a highly-active CD22-specific chimeric antigen receptor

CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Adrienne H., Haso, Waleed M., Orentas, Rimas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586/
https://www.ncbi.nlm.nih.gov/pubmed/23734316
http://dx.doi.org/10.4161/onci.23621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586/
https://www.ncbi.nlm.nih.gov/pubmed/23734316
http://dx.doi.org/10.4161/onci.23621

Ejemplares similares